Propranolol-d7 hydrochloride(Synonyms: 盐酸普萘洛尔 d7 (盐酸盐))

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物,专注于信号通路和疾病研究领域。
Propranolol-d7 hydrochloride (Synonyms: 盐酸普萘洛尔 d7 (盐酸盐))

Propranolol D7 hydrochloride 是 Propranolol hydrochloride 的氘代物。Propranolol hydrochloride 是一种非选择性的 β-adrenergic receptor (βAR) 拮抗剂,对 β1AR 和 β2AR 具有高亲和力,Ki 值分别为 1.8 nM 和 0.8 nM。Propranolol hydrochloride 抑制 [3H]-DHA 与大鼠脑膜制剂的结合,IC50 为 12 nM。Propranolol hydrochloride 用于高血压,嗜铬细胞瘤,心肌梗塞,心律不齐,心绞痛和肥大心肌病的相关研究。

Propranolol-d7 hydrochloride(Synonyms: 盐酸普萘洛尔 d7 (盐酸盐))

Propranolol-d7 hydrochloride Chemical Structure

CAS No. : 1613439-56-7

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Propranolol D7 hydrochloride is a deuterium labeled Propranolol hydrochloride. Propranolol hydrochloride is a nonselective β-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively[1]. Propranolol hydrochloride inhibits [3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM[2]. Propranolol hydrochloride is used for the study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy[3].

IC50 & Target

IC50: 12 nM (βAR)[1]

分子量

302.85

Formula

C16H15D7ClNO2

CAS 号

1613439-56-7

中文名称

盐酸普萘洛尔 d7 (盐酸盐)

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Galandrin S, et al. Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol. 2006 Nov;70(5):1575-84.

    [2]. Briley M, et al. Evidence against beta-adrenoceptor blocking activity of diltiazem, a drug with calcium antagonist properties. Br J Pharmacol. 1980 Aug;69(4):669-73.

    [3]. Al-Majed AA, et al. Propranolol. Profiles Drug Subst Excip Relat Methodol. 2017;42:287-338.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务